General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Direct Share Purchase Plan Disclaimer

The material on this site is directed only at persons resident in Switzerland.

The following information and documents do not constitute a solicitation or offer, or recommendation to buy or sell Novartis shares, to effect any transactions, to conclude any legal act of any kind whatsoever, or to subscribe to services made to persons residing in jurisdictions where such solicitation, offer or recommendation requires a local license.

The following information and documents are not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the publication or availability of the Novartis Webpage is prohibited. Persons in respect of whom such prohibitions apply must not access the following information and documents.

The Direct Share Purchase Plan is open to shareholders and investors residing in Switzerland. Due to legal restrictions, investors residing outside Switzerland may not download the documents related to the Direct Share Purchase Plan and/or access further information on the Direct Share Purchase Plan.

The Direct Share Purchase Plan is regulated by Swiss Law.

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014